Clinical Trial Update: Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase IIb study evaluating GFT505 vs placebo in non-alcoholic steatohepatitis (NASH) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• GFT505

Snippet

Sponsor: Genfit | Conditions: Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2022-11-03